Dexamethasone: A boon for critically ill COVID-19 patients?

Simple item page
dc.contributor.authorShailesh Kumar Patel
dc.contributor.authorG. Saikumar
dc.contributor.authorJigyasa Rana
dc.contributor.authorJaideep Dhama
dc.contributor.authorMohd. Iqbal Yatoo
dc.contributor.authorRuchi Tiwari
dc.contributor.authorAlfonso J. Rodríguez‐Morales
dc.contributor.authorKuldeep Dhama
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T13:57:28Z
dc.date.available2026-03-22T13:57:28Z
dc.date.issued2020
dc.descriptionCitaciones: 44
dc.identifier.doi10.1016/j.tmaid.2020.101844
dc.identifier.urihttps://doi.org/10.1016/j.tmaid.2020.101844
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/43711
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofTravel Medicine and Infectious Disease
dc.sourceIndian Veterinary Research Institute
dc.subjectCritically ill
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectDexamethasone
dc.subjectMedicine
dc.subject2019-20 coronavirus outbreak
dc.subjectIntensive care medicine
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subjectMEDLINE
dc.subjectVirology
dc.titleDexamethasone: A boon for critically ill COVID-19 patients?
dc.typearticle

Files

Collections

Artículo Científico Publicado